All enrolled infants predicted to develop SMA type 1 based on the copy number of SMN2 were able to sit independently for more than 30 s within 18 months posttreatment, while all children with SMA type 2 could stand independently before 24 months. The gene discussed is SMN2; the disease is spinal muscular atrophy, type 1.